SCHEMBL356929

SCHEMBL356929

CCc1nnc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HRH3 Q9Y5N1 6/20 0.32
RXFP1 Q9HBX9 1/20 0.32
RIPK2 O43353 1/20 0.31
PDGFRB P09619 1/20 0.31
KIT P10721 1/20 0.31
SRC P12931 1/20 0.31
FLT3 P36888 1/20 0.31
SIK1 P57059 1/20 0.31
RIPK4 P57078 1/20 0.31
DDR1 Q08345 1/20 0.31
RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354786 0.78 GPR119 (0.40)
SCHEMBL357439 0.76 CHIA (0.40) MEN1HTTLMNAHRH3RIPK2
SCHEMBL10140747 0.75 MALT1 (0.37) MEN1KMT2AALDH1A1RIPK2PDGFRB
SCHEMBL356620 0.75 GPR119 (0.45) MEN1KMT2A
SCHEMBL357038 0.75 RIPK2 (0.38) MEN1KMT2ARIPK2PDGFRBKIT
SCHEMBL356277 0.74 GPR119 (0.32) MEN1KMT2AALDH1A1RIPK2PDGFRB
SCHEMBL358364 0.74 GPR119 (0.36) RIPK2PDGFRBKITSRCFLT3
SCHEMBL354783 0.74 RIPK2 (0.35) MEN1RIPK2PDGFRBKITSRC
SCHEMBL355724 0.73 GPR119 (0.40) MEN1KMT2ARIPK2PDGFRBKIT
SCHEMBL356834 0.72 RIPK2 (0.32) RIPK2PDGFRBKITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 MEN1 4883/4885KMT2A 2953/4885ALDH1A1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.